🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  2. Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 1 other active

    1 trial

  3. Phase I Study of Plitidepsin Administered Intravenously as a Single Dose in Healthy Volunteers

    Lacuna Pharma Pty Ltd

    Virus diseases

    phase 1 other active

    1 trial

  4. Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.

    Lacuna Pharma Pty Ltd

    Androgenetic alopecia

    phase 1 other active

    1 trial

  5. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  6. Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  7. Phase I study of MGY825 in patients with lung cancer

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients

    phase 1 other active

    1 trial

  8. Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

  9. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  10. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  11. Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced solid tumors

    phase 1 other active

    1 trial

  12. Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

    Lacuna Pharma Pty Ltd

    Immune-mediated necrotizing myopathy, Antiphospholipid syndrome, Behçet’s Syndrome, Bullous pemphigoid, Dermatomyositis, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  13. Phase Ib Dose Finding Study of [177Lu]Lu-NeoB in Combination with RT and TMZ in Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  14. Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  15. Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

    Lacuna Pharma Pty Ltd

    Bullous pemphigoid, Behçet’s Syndrome, Dermatomyositis, Antiphospholipid syndrome, Immune-mediated necrotizing myopathy, Immune Thrombocytopenia

    phase 1 other active

    1 trial

  16. Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients with Parkinson’s Disease

    Lacuna Pharma Pty Ltd

    Parkinson’s Disease

    phase 1 other active

    1 trial

  17. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 1 small molecule terminated

    1 trial

  18. Placebo

    Madrigal Pharmaceuticals EU Limited

    Drug Safety

    phase 1 small molecule completed

    2 trials

  19. Placebo

    IONIS PHARMACEUTICALS INC

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 1 small molecule completed

    1 trial

  21. Placebo

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 1 small molecule completed

    1 trial

  22. Placebo

    Mirum Pharmaceuticals International B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  23. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    D-limonene and THC Pharmacodynamics

    phase 1 small molecule completed

    1 trial

  24. Placebo

    Eloxx Pharmaceuticals

    Genetic Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources